Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use ; Drug Substitution* ; Hypertension*/drug therapy; Sorbitol/*analogs & derivatives; Adult ; Aged ; Aged, 80 and over ; Blood Pressure ; Blood Pressure Monitoring, Ambulatory ; Humans ; Hypoglycemic Agents/therapeutic use ; Japan ; Middle Aged ; Multicenter Studies as Topic ; Prospective Studies ; Randomized Controlled Trials as Topic ; Sorbitol/therapeutic use ; Young Adult
    • Abstract:
      Introduction: Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension more effectively than a dipeptidyl peptidase (DPP)-4 inhibitor in patients with T2D.
      Methods and Analysis: This study is a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group trial. Sixty participants with T2D and hypertension who have been treated with a DPP-4 inhibitor for more than 4 weeks and who have a glycated haemoglobin A1c (HbA1c) level of 6.0%-9.0% will be randomised based on age, body mass index (BMI) and HbA1c to continue taking their DPP-4 inhibitor or to switch to luseogliflozin 2.5 mg once daily for 8 weeks. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) will be performed twice at baseline and at the end of the study. All participants will continue their diet and exercise therapy, and the doses of concomitant medications will not be adjusted during the study. The primary endpoint is the effect of luseogliflozin on the mean change in systolic blood pressure (SBP) during the night, as measured by ABPM. The secondary endpoints are mean change in diastolic blood pressure (DBP) during the night, 24 hours of SBP and DBP, daytime SBP and DBP, pulse rate, BP M-value, trough SBP and DBP for 1 hour before the next dose, and other laboratory parameters. The sample size was calculated for a two-sided test at 90% power for the detection of a difference between treatments.
      Ethics and Dissemination: The Ethics Review Board of Hokkaido University Hospital has approved the protocol. The results will be disseminated in peer-reviewed journals and at scientific conferences.
      Trial Registration Numbers: The University Hospital Medical Information Network (UMIN000031451); Japan Registry of Clinical Trials (jRCTs011180019); Pre-results.
      Competing Interests: Competing interests: AN has received honoraria for lectures from Sanofi, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Eli Lilly Japan, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Takeda Pharmaceutical, Astellas, Kowa Pharmaceutical, Ono, Nippon Boehringer Ingelheim, and Taisho Toyama Pharmaceutical, and has obtained research support from Mitsubishi Tanabe Pharma, Daiichi Sankyo, MSD, Novo Nordisk Pharma, Novartis Pharma, AstraZeneca, Dainippon Sumitomo Pharma, Life Scan Japan, and Taisho Pharmaceutical Co., Ltd. YK has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca, Mitsubishi Tanabe Pharma Co., Ltd., MSD, Ono Pharmaceutical Co., Ltd., Sanofi, Shionogi & Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. TA has received honoraria for lectures from Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Pfizer, and Eli Lilly, and has received research funding from Astellas Pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Daiichi Sankyo, and Otsuka Pharmaceutical. HM has received honoraria for lectures from Astellas Pharma, AstraZeneca, Dainippon Pharma, Eli Lilly, Kissei, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Novartis Pharma, and Sanofi, and has received research funding from Astellas Pharma, Astra‐Zeneca, Eli Lilly, and Mitsubishi Tanabe Pharma.
      (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
    • References:
      J Hypertens. 2016 Feb;34(2):167-75. (PMID: 26682782)
      Circulation. 2019 Apr 30;139(18):2089-2097. (PMID: 30586745)
      Arch Intern Med. 2005 Jun 27;165(12):1410-9. (PMID: 15983291)
      Lancet. 1988 Aug 13;2(8607):397. (PMID: 2899801)
      Int J Cardiovasc Imaging. 2014 Jan;30(1):57-65. (PMID: 24096641)
      J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9. (PMID: 24602971)
      PLoS One. 2018 Dec 12;13(12):e0208796. (PMID: 30540837)
      Lancet. 2010 Jun 26;375(9733):2215-22. (PMID: 20609967)
      N Engl J Med. 2015 Jul 16;373(3):232-42. (PMID: 26052984)
      BMJ. 1998 Sep 12;317(7160):703-13. (PMID: 9732337)
      BMJ. 2011 Jun 24;342:d3621. (PMID: 21705406)
      Diabetes Obes Metab. 2016 Mar;18(3):241-8. (PMID: 26511213)
      N Engl J Med. 2013 Oct 3;369(14):1327-35. (PMID: 23992602)
      N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
      J Clin Hypertens (Greenwich). 2017 Oct;19(10):948-955. (PMID: 28736895)
      Diabetes Care. 2015 Mar;38(3):420-8. (PMID: 25271206)
      Hypertension. 2001 Oct;38(4):852-7. (PMID: 11641298)
      Prim Care Diabetes. 2011 Oct;5(3):167-73. (PMID: 21546328)
      N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
      N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
      J Hypertens. 2002 Nov;20(11):2183-9. (PMID: 12409956)
      N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
    • Contributed Indexing:
      Keywords: cardiology; diabetes & endocrinology; hypertension
    • Molecular Sequence:
      UMIN-CTR UMIN000031451
    • Accession Number:
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Hypoglycemic Agents)
      506T60A25R (Sorbitol)
      C596HWF74Z (1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol)
    • Publication Date:
      Date Created: 20200209 Date Completed: 20210413 Latest Revision: 20240328
    • Publication Date:
      20240329
    • Accession Number:
      PMC7044823
    • Accession Number:
      10.1136/bmjopen-2019-034883
    • Accession Number:
      32034028